NZ600674A - Quinoline amide m1 receptor positive allosteric modulators - Google Patents
Quinoline amide m1 receptor positive allosteric modulatorsInfo
- Publication number
- NZ600674A NZ600674A NZ600674A NZ60067410A NZ600674A NZ 600674 A NZ600674 A NZ 600674A NZ 600674 A NZ600674 A NZ 600674A NZ 60067410 A NZ60067410 A NZ 60067410A NZ 600674 A NZ600674 A NZ 600674A
- Authority
- NZ
- New Zealand
- Prior art keywords
- quinoline
- carboxamide
- methyl
- positive allosteric
- receptor positive
- Prior art date
Links
- -1 Quinoline amide Chemical class 0.000 title abstract 2
- 230000003281 allosteric effect Effects 0.000 title 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- QDONIOGKYDEWKD-FPOVZHCZSA-N 4-[(2-ethoxypyridin-4-yl)methyl]-n-[(3r,4s)-3-hydroxyoxan-4-yl]quinoline-2-carboxamide Chemical compound C1=NC(OCC)=CC(CC=2C3=CC=CC=C3N=C(C=2)C(=O)N[C@@H]2[C@H](COCC2)O)=C1 QDONIOGKYDEWKD-FPOVZHCZSA-N 0.000 abstract 1
- VPMUJEOFHFOHAZ-ICSRJNTNSA-N 4-[(6-chloropyridin-3-yl)methyl]-n-[(1s,2s)-2-hydroxycyclohexyl]quinoline-2-carboxamide Chemical compound O[C@H]1CCCC[C@@H]1NC(=O)C1=CC(CC=2C=NC(Cl)=CC=2)=C(C=CC=C2)C2=N1 VPMUJEOFHFOHAZ-ICSRJNTNSA-N 0.000 abstract 1
- OEUUDFHQOHQOSO-YBCGLMIHSA-N 4-[fluoro-(6-methoxypyridin-3-yl)methyl]-n-[(3r,4s)-3-hydroxyoxan-4-yl]quinoline-2-carboxamide;hydrate Chemical compound O.C1=NC(OC)=CC=C1C(F)C1=CC(C(=O)N[C@@H]2[C@H](COCC2)O)=NC2=CC=CC=C12 OEUUDFHQOHQOSO-YBCGLMIHSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 abstract 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28753509P | 2009-12-17 | 2009-12-17 | |
| PCT/US2010/060007 WO2011084368A1 (en) | 2009-12-17 | 2010-12-13 | Quinoline amide m1 receptor positive allosteric modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ600674A true NZ600674A (en) | 2013-05-31 |
Family
ID=44305688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ600674A NZ600674A (en) | 2009-12-17 | 2010-12-13 | Quinoline amide m1 receptor positive allosteric modulators |
Country Status (41)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CN105037492A (zh) * | 2010-02-11 | 2015-11-11 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| AR081402A1 (es) | 2010-05-17 | 2012-08-29 | Envivo Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato |
| WO2011159554A1 (en) * | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| WO2012158474A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| JP6211509B2 (ja) | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| MX2016001942A (es) * | 2013-09-27 | 2016-06-02 | Hoffmann La Roche | Derivados de indol e indazol. |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CA2930961A1 (en) * | 2014-01-22 | 2015-07-30 | F. Hoffmann-La Roche Ag | Fluoro-naphthyl derivatives |
| WO2015190564A1 (ja) * | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| EP3692991A1 (de) | 2015-06-09 | 2020-08-12 | Bayer Pharma Aktiengesellschaft | Positiv allosterische modulatoren des muskarinergen m2 rezeptors |
| MA42769B1 (fr) * | 2015-09-10 | 2019-12-31 | Suven Life Sciences Ltd | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
| WO2017099969A1 (en) * | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Tetrahydroquinoxaline m1 receptor positive allosteric modulators |
| KR20180110132A (ko) | 2016-02-16 | 2018-10-08 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 |
| WO2017151449A1 (en) * | 2016-03-04 | 2017-09-08 | Merck Sharp & Dohme Corp. | M1 receptor positive allosteric modulator compounds and methods of use thereof |
| CN109689654A (zh) | 2016-07-11 | 2019-04-26 | 拜耳医药股份有限公司 | 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途 |
| MX389592B (es) | 2016-09-02 | 2025-03-20 | Suven Life Sciences Ltd | Moduladores alostericos positivos del receptor m1 muscarinico |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| WO2018063552A1 (en) | 2016-09-30 | 2018-04-05 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| EA035599B1 (ru) * | 2017-04-13 | 2020-07-14 | Сувен Лайф Сайенсиз Лимитед | Позитивные аллостерические модуляторы мускариновых m1-рецепторов |
| CA3068209A1 (en) * | 2017-06-20 | 2018-12-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2018235838A1 (ja) | 2017-06-20 | 2018-12-27 | 武田薬品工業株式会社 | 複素環化合物 |
| MA50464A (fr) * | 2017-10-27 | 2021-06-02 | Suven Life Sciences Ltd | Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
| EP3858828A4 (en) * | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| EP3858823A4 (en) | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | Condensed-cyclic compound |
| EP3867254B1 (en) | 2018-10-17 | 2023-05-31 | Suven Life Sciences Limited | Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2020086864A1 (en) | 2018-10-24 | 2020-04-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| KR20030027094A (ko) | 2000-08-29 | 2003-04-03 | 야마노우치세이야쿠 가부시키가이샤 | 신규 에스테르 또는 아미드 유도체 |
| EP1596867A4 (en) | 2003-02-19 | 2006-03-22 | Merck & Co Inc | TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR |
| MXPA05009722A (es) * | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
| SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| JP4740152B2 (ja) * | 2003-12-23 | 2011-08-03 | セロドス アクスイェ セルスカブ | 末梢性５−ｈｔ受容体の修飾因子 |
| US20070185090A1 (en) * | 2004-03-17 | 2007-08-09 | Jakob Busch-Petersen | Muscarinic acetylchoine receptor antagonists |
| JP5192389B2 (ja) * | 2005-12-05 | 2013-05-08 | メルク・シャープ・エンド・ドーム・コーポレイション | キノロンｍ１レセプター陽性アロステリックモジュレータ |
| CN101321733A (zh) * | 2005-12-05 | 2008-12-10 | 默克公司 | 喹诺酮m1受体阳性变构调节剂 |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
| EP2268280B1 (en) * | 2008-03-21 | 2013-04-24 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| NZ592961A (en) | 2008-11-20 | 2012-09-28 | Merck Sharp & Dohme | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| CA2750708A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators |
| EP2421366B1 (en) | 2009-04-20 | 2013-08-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
| AU2010286683B9 (en) | 2009-08-31 | 2014-09-04 | Merck Sharp & Dohme Llc | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
| EP2490692B1 (en) | 2009-10-21 | 2016-11-16 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| US8664387B2 (en) | 2009-12-14 | 2014-03-04 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone M1 receptor positive allosteric modulators |
| US8383638B2 (en) | 2009-12-21 | 2013-02-26 | Merck Sharp & Dohme | Aminobenzoquinazolinone M1 receptor positive allosteric modulators |
| EP2575454B1 (en) | 2010-05-28 | 2018-08-29 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide m1 receptor positive allosteric modulators |
| US8557992B2 (en) | 2010-06-15 | 2013-10-15 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators |
| WO2011159554A1 (en) | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| WO2012158474A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
-
2010
- 2010-12-13 US US13/515,724 patent/US9199939B2/en active Active
- 2010-12-13 BR BR112012014180A patent/BR112012014180A2/pt active Search and Examination
- 2010-12-13 JP JP2012544670A patent/JP5651708B2/ja not_active Expired - Fee Related
- 2010-12-13 CN CN201080057292.2A patent/CN102651970B/zh not_active Expired - Fee Related
- 2010-12-13 ME MEP-2016-106A patent/ME02421B/me unknown
- 2010-12-13 NZ NZ600674A patent/NZ600674A/xx not_active IP Right Cessation
- 2010-12-13 HR HRP20160574TT patent/HRP20160574T1/hr unknown
- 2010-12-13 KR KR1020127015521A patent/KR101494059B1/ko not_active Expired - Fee Related
- 2010-12-13 EA EA201290519A patent/EA022494B1/ru not_active IP Right Cessation
- 2010-12-13 PL PL10841821.1T patent/PL2512243T3/pl unknown
- 2010-12-13 ES ES10841821.1T patent/ES2575154T3/es active Active
- 2010-12-13 EP EP10841821.1A patent/EP2512243B1/en active Active
- 2010-12-13 CA CA2782347A patent/CA2782347C/en not_active Expired - Fee Related
- 2010-12-13 RS RS20160369A patent/RS54798B1/sr unknown
- 2010-12-13 DK DK10841821.1T patent/DK2512243T3/en active
- 2010-12-13 PT PT108418211T patent/PT2512243E/pt unknown
- 2010-12-13 SG SG2012044095A patent/SG181719A1/en unknown
- 2010-12-13 UA UAA201208772A patent/UA106406C2/ru unknown
- 2010-12-13 PE PE2012000830A patent/PE20121613A1/es not_active Application Discontinuation
- 2010-12-13 GE GEAP201012786A patent/GEP201606506B/en unknown
- 2010-12-13 AU AU2010340142A patent/AU2010340142B2/en not_active Ceased
- 2010-12-13 MX MX2012007013A patent/MX336774B/es unknown
- 2010-12-13 MA MA35061A patent/MA33920B1/fr unknown
- 2010-12-13 WO PCT/US2010/060007 patent/WO2011084368A1/en not_active Ceased
- 2010-12-13 PH PH1/2012/501222A patent/PH12012501222A1/en unknown
- 2010-12-13 HU HUE10841821A patent/HUE029734T2/en unknown
- 2010-12-13 SI SI201031184A patent/SI2512243T1/sl unknown
- 2010-12-16 TW TW099144262A patent/TWI412525B/zh not_active IP Right Cessation
- 2010-12-17 AR ARP100104723A patent/AR079510A1/es unknown
-
2012
- 2012-05-17 TN TNP2012000231A patent/TN2012000231A1/en unknown
- 2012-06-03 IL IL220130A patent/IL220130A0/en unknown
- 2012-06-12 ZA ZA2012/04313A patent/ZA201204313B/en unknown
- 2012-06-14 HN HN2012001265A patent/HN2012001265A/es unknown
- 2012-06-14 CL CL2012001605A patent/CL2012001605A1/es unknown
- 2012-06-15 DO DO2012000167A patent/DOP2012000167A/es unknown
- 2012-06-15 NI NI201200107A patent/NI201200107A/es unknown
- 2012-06-15 GT GT201200201A patent/GT201200201A/es unknown
- 2012-06-15 CO CO12101581A patent/CO6551729A2/es unknown
- 2012-06-15 CR CR20120327A patent/CR20120327A/es unknown
- 2012-06-19 EC ECSP12011983 patent/ECSP12011983A/es unknown
-
2015
- 2015-11-18 US US14/945,005 patent/US20160075656A1/en not_active Abandoned
-
2016
- 2016-07-05 CY CY20161100625T patent/CY1117726T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ600674A (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| NZ592961A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| IN2012DN02968A (pl) | ||
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| PH12013500247A1 (en) | Heterocyclic compound and use thereof | |
| EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
| HRP20151017T1 (hr) | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida | |
| NZ601656A (en) | Pyridyloxyindoles inhibitors of VEGF-R2 and use thereof for treatment of disease | |
| NZ598269A (en) | Aryl sulphone derivatives as calcium channel blockers | |
| NZ617334A (en) | Cyclopropyl amine derivatives | |
| MY160075A (en) | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| NZ705144A (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| HRP20150569T1 (hr) | 5-(fenil/piridinil-etinil)-2-piridin/2-pirimidin-karboksamidi kao modulatori za mglur5 | |
| PL2032534T3 (pl) | 4-[(3-fluorofenoksy)fenylometylo]piperydyno-metanosulfonian: zastosowanie, proces syntezy i kompozycje farmaceutyczne | |
| PH12015500489A1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinsons disease | |
| BR0309778A (pt) | Compostos 3,4-di-hidroquinolin-2(1h)-ona como antagonistas do receptor nr2b | |
| WO2009134668A3 (en) | 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators | |
| NZ608697A (en) | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators | |
| WO2009117283A3 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
| MX2013007411A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3). | |
| ATE498622T1 (de) | Prolinamidtetrazolderivate als nk3- rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: SCHERING CORPORATION, US Free format text: OLD OWNER(S): MERCK SHARP AND DOHME CORP. |
|
| ERR | Error or correction |
Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS; FILING DATE: 18 JUN 2012; STATUS: REJECTED; TITLE: QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS; FILING DATE: 18 SEP 2012; STATUS: PROPOSED; Effective date: 20130312 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 DEC 2017 BY THOMSON REUTERS Effective date: 20140912 |
|
| LAPS | Patent lapsed |